Therapeutic synergy of anti-cancer compounds

Details Therapeutic synergy of anti-cancer compounds Therapeutic synergy of anti-cancer compounds

2006-11-07

2006-11-07

Marschel, Ardin H. (Department: 1614)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C549S200000, C514S449000

Reexamination Certificate

active

07132554

ABSTRACT:
This invention relates to a synergistic therapeutic combination of anti-cancer compounds which comprises a) a taxane, and b) a substance that binds to the epidermal growth factor receptor (EGFR) and blocks the ability of epidermal growth factor (EGF) to intitiate receptor activities which results in tumor growth inhibition, and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use.

REFERENCES:
patent: 4943533 (1990-07-01), Mendelsohn et al.
patent: 5558864 (1996-09-01), Bendig et al.
patent: 5705508 (1998-01-01), Ojima et al.
patent: 5891996 (1999-04-01), Mateo de Acosta del Rio et al.
patent: 6235883 (2001-05-01), Jakobovits et al.
patent: 6750246 (2004-06-01), Kadow et al.
patent: WO 01/27115 (2001-04-01), None
patent: WO 01/57027 (2001-08-01), None
Cecil, Textbook of Medicine, 21st Edition (2000), Goldman & Bennett (Editors), W.B. Saunders Company (Publisher), Chapter 198, pp. 1060-1074.
Tortora G, et al., “Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel . . . breast cancer cell growth”, Clin. Cancer Res. Apr. 1999; 5(4):875-81.
Inoue K, et al. “Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma,” Clin Cancer Res Dec. 2000; 6(12): 4874-84.
Karashima T, et al., “Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody C225 . . . ,” May 2002 Clin Cancer Research vol. 8, 1253-1264.
Cassinelli G, et al., “Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer,” 2002 Clin Cancer Research vol. 8: pp. 2647-2654.
Shionoya M et al., “DJ-927, a novel oral taxane, overcomes p-glycoprotein-mediated multidrug resistance in vitro and in vivo,” May 2003 Cancer Sci vol. 94(5): 459-466.
Sampath D et al., “MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo,” Sep. 2003 Mol Cancer Ther vol. 2: 873-884.
Ciardiello F and Tortora G, “Anti-epidermal growth factor receptor drugs in cancer therapy,” Expert Opinion Investig. Drugs 2002 vol. 11(6): 755-768.
Rose, W.C. et al., “Therapeutic Synergy of Oral Taxane BMS-275183 and CetuximabversusHuman Tumor Xenografts”, Clinical Cancer Research, vol. 10, pp. 7413-7417 (2004).
U.S. Appl. No. 60/680,691, filed May 13, 2005, Voi et al.

Affiliated with

Also associated with

Rating

Therapeutic synergy of anti-cancer compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic synergy of anti-cancer compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic synergy of anti-cancer compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3648269